Sugi Predict

Sugi Predict / Compounds / SCHEMBL2195682

SCHEMBL2195682

SCHEMBL2195682

Cc1ccc(CN(I)I)cc1.[Pt]=c1[nH]c(Cc2ccccc2)nn1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ KMT2A Q03164 4/20 0.37
▸ LMNA P02545 3/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ TP53 P04637 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ POLB P06746 4/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194665 0.94 KDM4E (0.38) SMN1; SMN2KMT2ALMNAMEN1POLB
SCHEMBL2198381 0.91 LMNA (0.39) SMN1; SMN2CYP2C19CYP1A2CYP3A4CYP2C9
SCHEMBL2196435 0.90 MEN1 (0.39) SMN1; SMN2CYP2C19CYP1A2CYP3A4CYP2C9
SCHEMBL2197397 0.90 CACNA1G (0.38) SMN1; SMN2KMT2AMEN1TP53MAPT
SCHEMBL2195871 0.87 CXCR2 (0.37) SMN1; SMN2
SCHEMBL2199132 0.86 CYP2C19 (0.36) SMN1; SMN2CYP2C19NPC1RAB9AKMT2A
SCHEMBL2195930 0.80 GAA (0.34) SMN1; SMN2KMT2AMAPTKDM4EALDH1A1
SCHEMBL2196817 0.79 NR1H2 (0.36) SMN1; SMN2TP53MAPTPOLBALDH1A1
SCHEMBL2196581 0.79 HSD17B10 (0.36) KMT2ALMNAMEN1MAPTHTT
SCHEMBL2195699 0.79 HSD17B10 (0.35) KMT2ALMNAMEN1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 — — US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 — — US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 — — US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 — — US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SMN1; SMN2 4069/4885CYP2C19 255/4885NPC1 3384/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 SMN1; SMN2 4069/4885CYP2C19 255/4885NPC1 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.